Italy’s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has formed a partnership with US-based VisualDx. This alliance aims to enhance the identification of individuals who may have blastic plasmacytoid dendritic cell neoplasm (BPDCN) by introducing artificial intelligence/machine learning (AI/ML) tools.
Understanding BPDCN
BPDCN is an aggressive orphan hematologic malignancy with a poor prognosis, with patients typically surviving only 8.7 to 14 months post-diagnosis. The disease presents as skin lesions and may involve the bone marrow, blood, central nervous system, lymph nodes, and viscera. Dermatologists are often the first to recognize BPDCN signs and biopsy suspicious lesions, after which pathologists can test for BPDCN by detecting certain biomarkers highly expressed on BPDCN cells.
Treatment Option: Tagraxofusp-erzs
Stemline Therapeutics’ tagraxofusp-erzs is a CD123-directed cytotoxin and the first and only approved treatment for patients with BPDCN, providing a critical therapeutic option for this rare and aggressive condition.-Fineline Info & Tech
Leave a Reply